Bristol-Myers Squibb announced April 17 that bulk suppliers Dobfar and Interchem have agreed not to supply the antibiotic compound to companies infringing Bristol's patent, which expires in 2002. At the end of March, Bristol-Myers Squibb reached a settlement with the generic firms Zenith Labs and Biocraft ("The Pink Sheet" April 2, T&G-12).
You may also be interested in...
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.